<DOC>
	<DOCNO>NCT00534118</DOCNO>
	<brief_summary>RATIONALE : Giving infusion donor lymphocyte may able kill cancer cell patient hematologic cancer come back donor stem cell transplant . PURPOSE : This clinical trial study well donor lymphocyte infusion work treat patient recurrent persistent hematologic cancer donor stem cell transplant .</brief_summary>
	<brief_title>Donor Lymphocyte Infusion Treating Patients With Recurrent Persistent Hematologic Cancer After Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate exceed 10 % patient recurrent persistent hematologic malignancy treat donor lymphocyte infusion . Secondary - Estimate complete response rate patient . - Assess toxicity donor lymphocyte infusion patient . OUTLINE : Patients receive four donor lymphocyte infusion least 1 month apart absence disease progression , unacceptable toxicity , uncontrolled graft-versus-host disease .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Has undergone allogeneic stem cell transplantation ( ASCT ) hematologic malignancy least 30 day ago No failure engraft follow transplant No active acute chronic graftversushost disease ( GVHD ) Minimal GVHD allow Persistent relapse disease ASCT , include 1 following : Chronic myelogenous leukemia ( CML ) , meet follow criterion : Molecular relapse ( may treat imatinib mesylate transplant ) , define follow : ASCT nonTcell deplete , negative bcr/abl document PCR posttransplant , bcr/abl detectable 2 consecutive PCR determination &gt; 30 day apart ASCT nonTcell deplete bcr/abl detectable PCR time day 180 posttransplant Cytogenetic relapse 36 month imatinib mesylate Relapsed chronic phase , accelerated phase , blastic phase CML 36 month imatinib mesylate Must currently chronic phase accelerate phase CML Patients blastic phase CML must attain second chronic phase Acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome , meet follow criterion : Molecular relapse , evidence &lt; 5 % blast bone marrow patient 's leukemiaspecific molecular abnormality detectable PCR Cytogenetic relapse , evidence &lt; 5 % blast bone marrow patient 's leukemiaspecific chromosome abnormality detectable standard cytogenetics time day 60 posttransplant Hematologic relapse , evidence &gt; 20 % blast bone marrow soft tissue recurrence Must treat chemotherapy transplant , study donor lymphocyte infusion ( DLI ) Multiple myeloma Relapsed disease recurrence Mprotein thalidomide salvage treatment Prior posttransplant documentation disappearance Mprotein immunofixation Residual progressive disease Rising Mprotein level time posttransplant ( measure 3month interval ) Original Mprotein detectable 6 month posttransplant Immune protein electrophoresis ( IPEP ) require show Mcomponent day 60 posttransplant pretransplant Residual ( &gt; 5 % ) plasma cell bone marrow Relapsed nonHodgkin lymphoma Hodgkin lymphoma Relapse progression disease must evidence within 3 month prior donor lymphocyte infusion physical exam , radiographic study , molecular study Tumor rebiopsied determine histology If EpsteinBarr virus ( EBV ) lymphoma suspect , peripheral blood must assay EBV genome ( i.e. , EBV DNA test PCR ) within past 30 day EBV infection associate pancytopenia Persistent refractory pancytopenia EBV genome detect PCR peripheral blood Refractory pancytopenia define pancytopenia poorly responsive growth factor and/or transfusion EBV lymphoproliferative disorder Clonal lymphadenopathy refractory standard therapy acyclovir immunoglobulin ( DLI may give rituximab ) Not candidate repeat ASCT Chimerism status require determine eligibility DLI Patients eligible allogeneic ASCT , DLI offer first option , full donor chimerism relapse therapy relapse disease Patients relapse underlying disease transplant achieve remission chemotherapy allow No CNS recurrence clear standard chemotherapy CNS remission status must maintain 2 week Original hematopoietic progenitor stem cell donor must available cell donation No syngeneic donor PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy â‰¥ 8 week Creatinine &lt; 3 mg/dL ABO/Rh CMV IgG/IgM status know No HIV1 HIV2 antibody Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month ( male ) 6 month ( female ) completion study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
</DOC>